“When you’re a public company . . . it constrains your strategy and decision making,” she says. “We’re financially solid and independent, and this allows us to grow without seeking external funding.”
“We’ve made some innovations in automation that have revolutionized microbiology,” Triva says, glancing over the vast warehouses and factories outside the window of her office. The new technology revolutionized diagnostics, making it easier to conduct routine tests for viruses and bacterial infections alike. “Before flocked swabs, they used aluminum wires to take nasal samples,” says Triva, grimacing.
A heartbreaking development occurred in 2014, when Daniele died at 54 after a seven-month battle with cancer. Stefania, who started working at the company right out of college and had been director of quality assurance and regulatory affairs, stepped up.
And I'm glad to have never contributed a single dollar to her profit margin.
Here's a headline for everybody...read carefully
Its really not any words, its a very nice thing that you get something like this?
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: svbizjournal - 🏆 334. / 59 続きを読む »